The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index; 3 of the 21 sources its claims cite were checked for support.
A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis
Open accessAbstract
Background: To examine the effectiveness and acceptability of an 8-week individual tailored cognitive behavioural therapy (CBT) intervention for the treatment of depressive symptoms in those newly diagnosed with multiple sclerosis. Methods: The current study presents a pilot, parallel group randomized controlled trial (RCT) with an allocation ratio of 1:1 conducted in a large research and teaching hospital in Melbourne, Australia. 30 individuals with a mean age of 36.93years (SD=9.63) who were newly diagnosed with multiple sclerosis (MS) (X=24.87months, SD=15.61) were randomized to the CBT intervention (n=15) or treatment as usual (TAU) (n=15). The primary outcome was level of depressive symptoms using the Beck Depression Inventory-II (BDI-II). Secondary outcomes were level of anxiety, fatigue and pain impact, sleep quality, coping, acceptance of MS illness, MS related quality of life, social support, and resilience. Tertiary outcomes were acceptability and adherence to the intervention. Results: Large between group treatment effects were found for level of depressive symptoms at post and at 20weeks follow-up (d=1.66-1.34). There were also small to large group treatment effects for level of anxiety, fatigue and pain impact, sleep quality, MS related quality of life, resilience, and social support at post and at 20weeks follow-up (d=0.17-1.63). There were no drop-outs and participants completed all treatment modules. All participants reported the treatment as 'very useful', and most (73.4%) reported that the intervention had addressed their problems 'completely'. Conclusions: These data suggest that the tailored early intervention is appropriate and clinically effective for the treatment of depressive symptoms in those newly diagnosed with MS. A larger RCT comparing the CBT intervention with an active comparative treatment with longer term follow-up and cost effectiveness analyses is warranted. The pilot trial has been retrospectively registered on 28/04/2016 with the ISRCTN registry (trial ID ISRCTN10423371). © 2016 The Author(s).
Overview
CoChat Summary
TL;DR
This pilot 1:1 randomized controlled trial tested an 8-week individualized CBT intervention for people newly diagnosed with MS and found large reductions in depressive symptoms versus treatment as usual at post-treatment and 20 weeks. The intervention was also reported as highly acceptable, with no dropouts and very high satisfaction.
Key findings
- In 30 participants (15 CBT, 15 TAU), the CBT group had significantly lower BDI-II scores at post-treatment and 20-week follow-up, with between-group effect sizes ranging from d = 1.34 to 1.66.
- Secondary outcomes favored CBT for fatigue impact and pain effects scores, with significant group differences at post and 20 weeks; reported effect sizes ranged from d = 0.75 to 1.03 for MFIS/PES.
- CBT also improved MS-related quality of life: significant differences were reported for the MSQOL physical health composite and mental health composite at post and 20 weeks, with effect sizes ranging from d = 0.70 to 1.04 and d = 1.00 to 1.03, respectively.
- All intervention participants (n = 15) reported the treatment as “very useful,” completed all homework and modules, had a very strong therapeutic alliance, and 100% said they would “definitely” recommend it to a close friend with MS; 73.4% said it addressed their problems “completely.”
Methods
- Pilot, parallel-group randomized controlled trial with 1:1 allocation to tailored CBT (n = 15) or treatment as usual (n = 15), conducted in a hospital setting in Melbourne, Australia.
- Included 30 individuals newly diagnosed with MS; all were within 5 years of diagnosis, and the sample had a mean age of 36.93 years (SD 9.63) and mean time since diagnosis of 24.87 months (SD 15.61).
- Baseline group differences were tested with ANOVAs; post-treatment and 20-week outcomes were tested with ANCOVAs controlling for baseline scores, gender, and ambulation status; effect sizes were calculated with Cohen’s d.
Limitations
- The paper states it was a preliminary pilot with a small sample size, only two therapists, reliance on self-report measures, a mostly educated and employed sample, and no active comparative intervention.
- It also states the follow-up was limited to 20 weeks and that treatment fidelity was not monitored by an independent rater and there were no audio recordings for therapist competency ratings.
- Evident from the text: blinding was not maintained after assignment, and clinicians who delivered the intervention also helped provide assessment questionnaires, which could introduce bias.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 0 Not valid · 8 Not checked · 45 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“A review of seven CBT studies (individual (3 studies), group (3 studies) and by computer (1 study)) found a medium treatment effect of 0.5 SD [12].”
§ A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis > Background
What the sources say
- Supportedcites [12] Hind D, Cotter J, Thake A, Bradburn M, Cooper C, Isaac C, House A. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:5. source
The Abstract (Results) identifies seven eligible studies: three individual, three group, and one computer-delivered. The Discussion (Principal findings) explicitly describes a medium treatment effect of 0.5 SD for depression in people with MS. The Results (Synthesis) show that this approximates the sensitivity-analysis estimate of 0.46 SD after an outlying study was removed. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was also a significant group difference on the RSA at post and at 20 week follow up (ds ranging from 0.44 to 0.57).”
§ A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis > Results > Analysis of secondary outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Linear models revealed that those in the CBT group, when compared to the TAU group, had significantly lower scores on the BDI-II at post and at 20 week follow up (ds ranging from 1.34 to 1.66).”
§ A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis > Results > Analysis of primary outcomes
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were significant group differences on the PSQI score at post and at 20 week follow up (ds ranging from 1.06 to 1.31).”
§ A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis > Results > Analysis of secondary outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were also significant group differences on the PSSS score at post and at 20 week follow up (ds ranging from 0.17 to 0.96).”
§ A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis > Results > Analysis of secondary outcomes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
11 more claims
Create a free account to see all 56 claims and every source verdict.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cognitive behavioral therapy (CBT), mindfulness, acceptance and commitment therapy (ACT) have considered as the most practical therapeutic methods in treating anxiety in patients affected by MS.”
From Psychological interventions for decreasing anxiety in people with multiple sclerosis (MS): A systematic review (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Relatedly, a recent study found significant reductions in levels of depressive and anxiety symptoms and higher levels of illness acceptance in individuals who were newly diagnosed with MS who undertook a tailored 8-week cognitive behavioural therapy programme for depression and anxiety (Kiropoulos et al., 2016).”
From Self-concept, illness acceptance and depressive and anxiety symptoms in people with multiple sclerosis. (2021) · cites this paper as Kiropoulos et al., 2016
Statistics that don’t add up
Each reported p-value recomputed from its test statistic and degrees of freedom.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“F(1, 29) = 10.54, p < 0.001”
§ A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis > Results > Analysis of secondary outcomes
Reported p < .001 · recomputed p = .003
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Doesn’t add upF(1, 29) = 10.54reported p < .001 · recomputed p = .003
“F(1, 29) = 10.54, p < .001”
- ConsistentF(1, 29) = 2.95reported p > .05 · recomputed p = .097
“F(1, 29) = 2.95, p > .05”
- ConsistentF(1, 29) = 8.2reported p < .01 · recomputed p = .008
“F(1, 29) = 8.20, p < .01”
- ConsistentF(1, 29) = 17.97reported p < .001 · recomputed p < .001
“F(1, 29) = 17.97, p < .001”
- ConsistentF(1, 29) = 7.7reported p < .01 · recomputed p = .010
“F(1, 29) = 7.70, p < .01”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234 · cited 3×
“There were significant group differences on the PSQI score at post and at 20 week follow up (ds ranging from 1.06 to 1.31).”
MethodInfluential(1970) · Cited by 24,983
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Design and analysis of pilot studies: recommendations for good practice
Lancaster, G. A., Dodd, S., & Williamson, P. R. (2004) · Journal of Evaluation in Clinical Practice · doi:10.1111/j..2002.384.doc.x · Cited by 2,572 · cited 1×
“A sample size of 30 was selected as this number has been recommended for pilot studies [27].”
MethodSTAI manual for the State-trait anxiety inventory
Cd, S. (1970) · Medical Entomology and Zoology · Cited by 2,492
A health-related quality of life measure for multiple sclerosis
Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W., & Ellison, G. W. (1995) · Quality of Life Research · doi:10.1007/bf02260859 · Cited by 1,132 · cited 1×
“The Multiple Sclerosis Quality of Life (MSQOL-54) [32] was used to measure MS related quality of life.”
MethodResilience in relation to personality and intelligence
Friborg, O., Barlaug, D., Martinussen, M., Rosenvinge, J. H., & Hjemdal, O. (2005) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.15 · Cited by 751 · cited 5×
“The 33-item Resilience Scale for Adults (RSA) [37] was used to measure level of resilience and investigates five main protective factors: personal competence, social competence, personal structure, family cohesion and social resources.”
MethodInfluentialDepression in multiple sclerosis: a review
Siegert, R. J. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.054635 · Cited by 718 · cited 1×
“The lifetime prevalence of depression among individuals with MS has been found to be 50% [5] and point prevalence rates range from 15 to 26% [6].”
BackgroundSocial support, type A behavior, and coronary artery disease.
Blumenthal, J. A., Burg, M. M., Barefoot, J., Williams, R. B., Haney, T., & Zimet, G. (1987) · Psychosomatic Medicine · doi:10.1097/00006842-198707000-00002 · Cited by 642
Folkman, S., & Lazarus, R. S. (2012) · PsycTESTS Dataset · doi:10.1037/t06501-000 · Cited by 440
Research works printed but not linked: 4
- First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
- Ritvo PG, Fischer JS, Miller DM, Andrews H, Paty DW, LaRocca NG. Multiple sclerosis quality of life inventory: a user’s manual. NY: New York, National Multiple Sclerosis Society; 1997.
- Luborsky L, Barber JP, Siqueland L, Johnson S, Najavits LM, Frank A, Daley D. The revised helping alliance questionnaire (HAQ-II). J Psychother Pract Res. 1996;5:260–71.
- Cohen J. Statistical power for the behavioural sciences. 2nd ed. Hillsdale: Erlbaum; 1988.
Cited by
Quality of life in adults with multiple sclerosis: A systematic review
Gil-González, I., Martín-Rodríguez, A., Conrad, R., & Pérez-San-Gregorio, M. Á. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-041249 · Cited by 263
“As in Ehde et al , 128 improvements in QoL were still maintained at 6-month follow-up.”
Psychological Interventions for the Treatment of Chronic Pain in Adults
Driscoll, M. A., Edwards, R. R., Becker, W. C., Kaptchuk, T. J., & Kerns, R. D. (2021) · Psychological Science in the Public Interest · doi:10.1177/15291006211008157 · Cited by 176
Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment
Solaro, C. M., Gamberini, G., & Masuccio, F. G. (2018) · CNS Drugs · doi:10.1007/s40263-018-0489-5 · Cited by 197
Harrison, A. M., Safari, R., Mercer, T. H., Picariello, F., van der Linden, M. L., White, C. M., Moss-Morris, R. E., & Norton, S. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458521996002 · Cited by 101
Ghielen, I., Rutten, S., Boeschoten, R. E., Houniet-de Gier, M., van Wegen, E. E. H., van den Heuvel, O. A., & Cuijpers, P. (2019) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2019.05.001 · Cited by 74
“(2016) [35] MS Depressive symptoms BDI-II 15 CBT 15 TAU BDI-II 0–0–1-1-0-00 (2) STAI”
BackgroundInfluential
Metadata
- Authors
- Kiropoulos, L. A., Kilpatrick, T., Holmes, A., & Threader, J.
- Affiliations
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Corresponding author
- Kiropoulos, Litza A.
- Venue
- BMC Psychiatry
- Published
- 2016-12
- Volume
- 16
- Issue
- 1
- Pages
- 435-435
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC5142334
- OpenAlex
- W2560152410
- Semantic Scholar
- 8417b1fa0dde2398037bacfc46f3d6cdd8e56e4a
- Cited by
- 50
- References
- 41
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 7 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 7 · 2019: 5 · 2018: 4
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- University of Melbourne Neurosciences and Behavioural Science domain research grant
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
- Keywords
- multiple sclerosis, depressive symptoms, cognitive behavioral therapy, personalized interventions, newly diagnosed multiple sclerosis, anxiety, fatigue, sleep quality, resilience, social support, quality of life, treatment acceptability, early psychological intervention
- MeSH terms
- Adaptation, Psychological, Adult, Anxiety, Australia, Cost-Benefit Analysis, Depression, Fatigue, Female, Health Services, Humans, Male, Multiple Sclerosis, Pilot Projects, Psychiatric Status Rating Scales, Quality of Life, Sleep Wake Disorders, Social Support, Cognitive Behavioral Therapy, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis. https://app.cochat.ai/papers/10.1186/s12888-016-1152-7
- The paper
- Kiropoulos, L. A., Kilpatrick, T., Holmes, A., & Threader, J. (2016). A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis. BMC Psychiatry. https://doi.org/10.1186/s12888-016-1152-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
